Literature DB >> 10880420

Brief antecedent ischemia enhances recombinant tissue plasminogen activator-induced coronary thrombolysis by adenosine-mediated mechanism.

K Przyklenk1, P Whittaker.   

Abstract

BACKGROUND: Clinical studies have implicated preinfarct angina (brief antecedent ischemia/reperfusion [I/R]) as a predictor of more rapid thrombolysis and lower rates of reocclusion. However, the effects of antecedent ischemia on the efficacy of thrombolysis have not been rigorously assessed. Using a canine model of coronary thrombosis, we aimed to (1) reproduce these clinical findings and (2) determine whether release of adenosine (a potent inhibitor of platelet aggregation via stimulation of platelet A(2) receptors) during brief I/R contributes to this improved patency. METHODS AND
RESULTS: To address our first objective, we compared the time required to achieve lysis with recombinant tissue plasminogen activator and patency during the first 2 hours after lysis in dogs in which 1-hour thrombotic occlusion was preceded by brief I/R (10-minute coronary occlusion/10-minute reperfusion) versus 20-minute uninterrupted perfusion (controls). Time to lysis was accelerated in the I/R group versus the control group (11+/-1 versus 35+/-6 minutes, P=0.004). In addition, the duration of subsequent reocclusion was reduced (17+/-12 versus 30+/-11 minutes), and the area of the flow-time profile (normalized to baseline flow x 120 minutes) was increased (64+/-12% versus 35+/-7%, P=0.04) in the I/R cohort. The protocol was then repeated, but all dogs were pretreated with the adenosine A(2)/A(1) antagonist CGS 15943 (CGS, 1.5 mg/kg). Time to lysis (38 versus 39 minutes) and subsequent patency were comparable in the CGS+control group versus the CGS+I/R group.
CONCLUSIONS: Brief antecedent I/R enhances the efficacy of coronary thrombolysis in this canine model, which is due, at least in part, to an adenosine-mediated mechanism.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10880420     DOI: 10.1161/01.cir.102.1.88

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  10 in total

1.  Adenosine and blood platelets.

Authors:  Hillary A Johnston-Cox; Katya Ravid
Journal:  Purinergic Signal       Date:  2011-02-08       Impact factor: 3.765

2.  In vitro platelet responsiveness to adenosine-mediated "preconditioning" is age-dependent.

Authors:  Karin Przyklenk; Peter Whittaker
Journal:  J Thromb Thrombolysis       Date:  2005-02       Impact factor: 2.300

3.  Lower Platelet Reactivity Is Associated with Presentation of Unstable Coronary Artery Disease.

Authors:  Tesse C Leunissen; Crystel M Gijsberts; Peter Paul Wisman; Albert Huisman; Maarten Ten Berg; Folkert W Asselbergs; Imo E Hoefer; Gerard Pasterkamp; Frans L Moll; Gert Jan de Borst; Mark Roest
Journal:  Int J Angiol       Date:  2016-10-24

4.  Adaptation of a photochemical method to initiate recurrent platelet-mediated thrombosis in small animals.

Authors:  Karin Przyklenk; Peter Whittaker
Journal:  Lasers Med Sci       Date:  2007-03       Impact factor: 3.161

5.  Fibrin architecture in clots: a quantitative polarized light microscopy analysis.

Authors:  Peter Whittaker; Karin Przyklenk
Journal:  Blood Cells Mol Dis       Date:  2008-12-02       Impact factor: 3.039

6.  Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis.

Authors:  K Przyklenk; A L Frelinger; M D Linden; P Whittaker; Y Li; M R Barnard; J Adams; M Morgan; H Al-Shamma; A D Michelson
Journal:  J Thromb Haemost       Date:  2009-11-17       Impact factor: 5.824

7.  Effect of adenosine A2 receptor stimulation on platelet activation-aggregation: differences between canine and human models.

Authors:  Matthew D Linden; Marc R Barnard; A L Frelinger; Alan D Michelson; Karin Przyklenk
Journal:  Thromb Res       Date:  2007-08-28       Impact factor: 3.944

8.  Effect of remote ischaemic conditioning on platelet reactivity and endogenous fibrinolysis in ST-elevation myocardial infarction: a substudy of the CONDI-2/ERIC-PPCI randomized controlled trial.

Authors:  Diana A Gorog; Mohamed Farag; Nikolaos Spinthakis; Derek M Yellon; Hans Erik Bøtker; Rajesh K Kharbanda; Derek J Hausenloy
Journal:  Cardiovasc Res       Date:  2021-01-21       Impact factor: 10.787

9.  2022 Update of the Consensus on the Rational Use of Antithrombotics and Thrombolytics in Veterinary Critical Care (CURATIVE) Domain 6: Defining rational use of thrombolytics.

Authors:  Claire R Sharp; Marie-Claude Blais; Corrin J Boyd; Benjamin M Brainard; Daniel L Chan; Armelle de Laforcade; Robert Goggs; Julien Guillaumin; Alex Lynch; Erin Mays; Duana McBride; Tommaso Rosati; Elizabeth A Rozanski
Journal:  J Vet Emerg Crit Care (San Antonio)       Date:  2022-07

10.  Analysis of risk factors of ST-segment elevation myocardial infarction in young patients.

Authors:  Wang Yunyun; Li Tong; Liu Yingwu; Liu Bojiang; Wang Yu; Hu Xiaomin; Li Xin; Peng Wenjin; JinFang Li
Journal:  BMC Cardiovasc Disord       Date:  2014-12-09       Impact factor: 2.298

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.